Involvement of Lysyl Oxidase in the Pathogenesis of Arterial Stiffness in Chronic Kidney Disease

The study aimed to evaluate the role of Lysyl Oxidase (LOX) in inducing aortic stiffness in chronic kidney disease (CKD) and to determine if a LOX inhibitor, β-aminopropionitrile (BAPN), could prevent aortic stiffness by reducing collagen cross-linking. The results showed that Nx mice had increased PWV and aortic wall remodeling compared to control mice and that collagen cross-linking was increased in parallel with the increase in total collagen in the aorta of Nx mice. In contrast, Nx mice that received BAPN treatment showed decreased cross-linked collagens and PWV compared to those receiving vehicle treatment. The study suggests that LOX may be an early and key mediator of aortic stiffness in CKD, and that BAPN treatment may prevent aortic stiffness by reducing collagen cross-linking.